Dec 01, · The purpose of this study was to investigate the efficacy and safety of the monoclonal antibody, rituximab, in relapsed or refractory hairy cell leukemia (HCL). Fifteen patients with relapsed or primary refractory HCL after nucleoside analogs received rituximab mg/m2 weekly for a total of 8 planned doses. An additional 4 doses could be administered to responders who had not achieved.
Jun 18, · The Question. What is your management approach to patients with relapsed/refractory hairy cell leukemia? My Response. Hairy cell leukemia (HCL) is an indolent B-cell malignancy, originally with a median survival of approximately four years. 1 Single-agent purine analog therapy with pentostatin or cladribine achieves complete remission (CR) rates of 70 to 90 percent and median relapse-free.
Some patients still have leukemia cells in their bone marrow after hairy cell leukemia treatment. This is called refractory leukemia. Some patients have a return of leukemia cells in the marrow and a decrease in normal blood cells after remission. This is called a relapse. Drug therapy that can be used to treat relapsed or refractory HCL includes.
Hairy cell leukemia is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). Hairy cell leukemia is a cancer of the blood and bone eazye.info rare type of leukemia gets worse slowly or does not get worse at all. The disease is called hairy cell leukemia because the leukemia cells look "hairy" when viewed under a microscope.